|
Jul 1
|
What Makes Sage Therapeutics (SAGE) a New Buy Stock
|
|
Jun 18
|
H.C. Wainwright sees potential competition for Sage from Biogen
|
|
Jun 17
|
Sage Therapeutics (SAGE) Soars 35.4%: Is Further Upside Left in the Stock?
|
|
Jun 17
|
Morning Movers: Sage Therapeutics surges after deal to be acquired by Supernus
|
|
Jun 16
|
Supernus Pharmaceuticals Snaps Up Beleaguered Sage Therapeutics
|
|
Jun 16
|
Sage Therapeutics Stock Soars 36% After Sale to Supernus Pharmaceuticals. What We Know.
|
|
Jun 16
|
Supernus makes depression drug play with $795m Sage buyout
|
|
Jun 16
|
Sector Update: Health Care Stocks Flat to Higher Premarket Monday
|
|
Jun 16
|
Sage, following Setbacks, to sell to Supernus for $561M
|
|
Jun 16
|
Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio
|
|
Mar 1
|
Sage Therapeutics, Inc. (SAGE): Among the Best Psychedelic Stocks to Buy in 2025
|
|
Feb 25
|
Is Sage Therapeutics, Inc. (SAGE) the Best Small-Cap Growth Stock to Buy Now?
|
|
Feb 13
|
Sage Therapeutics price target lowered to $12 from $14 at Scotiabank
|
|
Feb 12
|
Sage Therapeutics' Q4 Earnings Miss Mark, Revenues Plunge Y/Y
|
|
Feb 12
|
Q4 2024 SAGE Therapeutics Inc Earnings Call
|
|
Feb 12
|
Sage Therapeutics Inc (SAGE) Q4 2024 Earnings Call Highlights: Strong Prescription Growth Amid ...
|
|
Feb 11
|
Sage Therapeutics, Inc. (SAGE) Reports Q4 Loss, Lags Revenue Estimates
|
|
Feb 11
|
Sage Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Highlights Pipeline and Business Updates
|
|
Jan 30
|
The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen, Cytokinetics and Akero Therapeutics
|
|
Jan 29
|
Biotech Stock Roundup: SAGE Up on Declining BIIB's Offer, CYTK, AKRO Up on Updates
|